Matches in Wikidata for { <http://www.wikidata.org/entity/Q90685035> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- Q90685035 description "artículu científicu espublizáu n'ochobre de 2019" @default.
- Q90685035 description "im Oktober 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q90685035 description "scientific article published on 14 October 2019" @default.
- Q90685035 description "wetenschappelijk artikel" @default.
- Q90685035 description "наукова стаття, опублікована 14 жовтня 2019" @default.
- Q90685035 name "Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis" @default.
- Q90685035 name "Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis" @default.
- Q90685035 type Item @default.
- Q90685035 label "Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis" @default.
- Q90685035 label "Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis" @default.
- Q90685035 prefLabel "Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis" @default.
- Q90685035 prefLabel "Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis" @default.
- Q90685035 P1433 Q90685035-F9A525F0-A632-4F13-ABF5-3CBB8E9BED55 @default.
- Q90685035 P1476 Q90685035-B92832A4-E518-453A-B59B-7C7DD12CE832 @default.
- Q90685035 P2093 Q90685035-11141833-7F76-40BF-8F90-C9CF346A2650 @default.
- Q90685035 P2093 Q90685035-140BD137-5276-4939-BD01-A71A6C336785 @default.
- Q90685035 P2093 Q90685035-1AB473EC-65C1-41B5-92C8-D50089C70D64 @default.
- Q90685035 P2093 Q90685035-1E39773D-E424-46FA-B978-A6CE19685847 @default.
- Q90685035 P2093 Q90685035-3F1CFCDE-78B2-409A-9833-73E05F1C0B56 @default.
- Q90685035 P2093 Q90685035-45C640FE-1D49-4A6C-AA72-B85E097D4F5F @default.
- Q90685035 P2093 Q90685035-476365E5-5C4B-4E2B-85B0-AC1661FD2D30 @default.
- Q90685035 P2093 Q90685035-5CCF38DE-6931-4070-B2E9-7F996B8D88D4 @default.
- Q90685035 P2093 Q90685035-5E3C754A-FF0F-4A32-9AEC-121204B2167D @default.
- Q90685035 P2093 Q90685035-60C8CF64-AD10-4F8F-81D5-C766079CF390 @default.
- Q90685035 P2093 Q90685035-7304A3F8-8019-4CE4-A993-303E858FE232 @default.
- Q90685035 P2093 Q90685035-75349774-3CF9-49D7-A301-58221A72BC1D @default.
- Q90685035 P2093 Q90685035-7DD087C8-6B68-4251-806F-4C79FB3764E3 @default.
- Q90685035 P2093 Q90685035-9173382E-0E0E-45F2-A5ED-FF17D1267AE3 @default.
- Q90685035 P2093 Q90685035-9EE666D1-1FC1-420B-A4E4-61A631685F50 @default.
- Q90685035 P2093 Q90685035-A2C28FD3-C03F-4481-A6AF-88B1F25754E0 @default.
- Q90685035 P2093 Q90685035-A6F4CD74-8CEF-40A4-AF07-3574A0F7E596 @default.
- Q90685035 P2093 Q90685035-C6C56A46-D1F3-4938-95C0-BF477D43301C @default.
- Q90685035 P2093 Q90685035-F3208437-D9CC-4C56-ACB0-14316C0E7075 @default.
- Q90685035 P304 Q90685035-234A501B-0E44-4557-9E0D-D2E0082FC658 @default.
- Q90685035 P31 Q90685035-08D7A1BE-F13D-4478-A4EC-76B99B8A9E39 @default.
- Q90685035 P356 Q90685035-A6C1F783-FF25-4ACB-A93D-3A03DAA3AF9D @default.
- Q90685035 P433 Q90685035-B23F036A-F553-4C83-85A2-9BE1DDA548C3 @default.
- Q90685035 P478 Q90685035-1B66A6C1-DD83-426D-BEF4-CB2D12D4A11A @default.
- Q90685035 P50 Q90685035-70BB1756-8569-4727-98EB-A127A284AAF5 @default.
- Q90685035 P50 Q90685035-E06381C2-8C72-4F7F-9520-CEF1BD37550A @default.
- Q90685035 P577 Q90685035-ECDC1CFF-AD61-457F-9235-721E8FC4264C @default.
- Q90685035 P698 Q90685035-1D0CC194-119A-4A63-AEC6-E3B41FF075AF @default.
- Q90685035 P921 Q90685035-3444FD95-8549-4318-985D-C759E9F7DCD8 @default.
- Q90685035 P921 Q90685035-5A3F51AB-BE7E-4DDB-845C-3B73BF91C869 @default.
- Q90685035 P921 Q90685035-E68F0551-0E7D-4C26-A5ED-9A805E5690EA @default.
- Q90685035 P356 21678421.2019.1672750 @default.
- Q90685035 P698 31608711 @default.
- Q90685035 P1433 Q23928840 @default.
- Q90685035 P1476 "Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis" @default.
- Q90685035 P2093 "Alan Pestronk" @default.
- Q90685035 P2093 "Benjamin Rix Brooks" @default.
- Q90685035 P2093 "David Schoenfeld" @default.
- Q90685035 P2093 "Eric A Macklin" @default.
- Q90685035 P2093 "Hong Yu" @default.
- Q90685035 P2093 "Jason Walker" @default.
- Q90685035 P2093 "Jeremy Shefner" @default.
- Q90685035 P2093 "Johnny S Salameh" @default.
- Q90685035 P2093 "Katherine E Jackson" @default.
- Q90685035 P2093 "Katy Mahoney" @default.
- Q90685035 P2093 "Laura Simionescu" @default.
- Q90685035 P2093 "Mazen M Dimachkie" @default.
- Q90685035 P2093 "Michael D Weiss" @default.
- Q90685035 P2093 "Nazem Atassi" @default.
- Q90685035 P2093 "Paul E Barkhaus" @default.
- Q90685035 P2093 "Suma Babu" @default.
- Q90685035 P2093 "Swati Aggarwal" @default.
- Q90685035 P2093 "William S David" @default.
- Q90685035 P2093 "Zachary Simmons" @default.
- Q90685035 P304 "15-23" @default.
- Q90685035 P31 Q13442814 @default.
- Q90685035 P356 "10.1080/21678421.2019.1672750" @default.
- Q90685035 P433 "1-2" @default.
- Q90685035 P478 "21" @default.
- Q90685035 P50 Q15968540 @default.
- Q90685035 P50 Q95746107 @default.
- Q90685035 P577 "2019-10-14T00:00:00Z" @default.
- Q90685035 P698 "31608711" @default.
- Q90685035 P921 Q206901 @default.
- Q90685035 P921 Q412178 @default.
- Q90685035 P921 Q42824440 @default.